Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
The NHS has set an ambitious goal to be the worlds first net zero national health service with clear goals to achieve before 2040.2
Trelegy: Now a carbon neutral triple therapy inhaler, as certified by the Carbon Trust.1
One part of delivering GSK’s commitment to have a net zero impact on climate and net positive impact on nature by 2030.
What is carbon neutrality?
Hydrofluorocarbons contained in pressurised metered dose inhalers (pMDIs) are potent greenhouse gases and have a high Global Warming Potential (GWP). Dry powder inhalers (DPIs) don’t contain hydrofluorocarbons, however it doesn’t mean they don’t have an impact – almost everything we do as humans has an impact.
We have, and continue, to innovate in our manufacturing and distribution of Trelegy Ellipta to make it’s footprint on humanity as low as possible – but now we have taken one step further and offset the small carbon footprint it does have. This is what we mean by carbon neutral.
How have we achieved it?
To offset the small carbon footprint Trelegy Ellipta has, we are supporting a community re-forestation project based in Ghana – a project planting trees and improving sanitation and health.
This project restores forest reserves that have been degraded due to over exploitation, bush fires and conversion to agriculture.
In addition to delivering emissions removals to take climate action, this project aims to deliver a number of other benefits including:
- providing work and opportunities for economic growth
- Projects with a gender equality focus
- Improving sanitation and access to clean water
-
COP 26
With our new net zero targets, we have joined the Race to Zero: a global UN campaign, which aims to build momentum around the shift to a decarbonised economy in line with the climate summit, COP 26.
Trelegy Ellipta prescribing information
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.3
References
- Certification of carbon neutrality for Trelegy Ellipta
- https://www.england.nhs.uk/greenernhs/a-net-zero-nhs/ (Accessed November 2021)
- Trelegy Ellipta SmPC
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2021 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
The Ellipta range was developed in collaboration with
November 2021 | PM-GB-FVU-WCNT-210010 (V2.0)
